

Ehsan Malek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9440699/publications.pdf>

Version: 2024-02-01

85
papers

2,084
citations

394421

19
h-index

254184

43
g-index

85
all docs

85
docs citations

85
times ranked

3314
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. <i>Leukemia</i> , 2019, 33, 2266-2275.	7.2	385
2	Novel therapies emerging in oncology to target the TGF- β 2 pathway. <i>Journal of Hematology and Oncology</i> , 2021, 14, 55.	17.0	192
3	Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer. <i>Oncotarget</i> , 2014, 5, 8027-8038.	1.8	177
4	Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e459-e469.	4.6	174
5	NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 11-20.	4.9	142
6	NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1154-1165.	4.9	113
7	Myeloid-derived suppressor cells: The green light for myeloma immune escape. <i>Blood Reviews</i> , 2016, 30, 341-348.	5.7	105
8	Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib. <i>Leukemia</i> , 2015, 29, 2184-2191.	7.2	88
9	Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma. <i>Oncotarget</i> , 2015, 6, 3098-3110.	1.8	69
10	Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. <i>Cancer</i> , 2020, 126, 5077-5087.	4.1	47
11	Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2017, 7, e579-e579.	6.2	40
12	MicroRNAs in Brain Metastases: Potential Role as Diagnostics and Therapeutics. <i>International Journal of Molecular Sciences</i> , 2014, 15, 10508-10526.	4.1	37
13	Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure. <i>British Journal of Haematology</i> , 2020, 188, 501-510.	2.5	36
14	Metabolic tumor volume on interim PET is a better predictor of outcome in diffuse large B-cell lymphoma than semiquantitative methods. <i>Blood Cancer Journal</i> , 2015, 5, e326-e326.	6.2	34
15	Gastrointestinal Microbiome and Mycobiome Changes during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1511-1519.	2.0	33
16	Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells. <i>Oncotarget</i> , 2014, 5, 12358-12370.	1.8	31
17	A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2019, 25, 4231-4237.	7.0	30
18	Interference of Therapeutic Monoclonal Antibodies With Routine Serum Protein Electrophoresis and Immunofixation in Patients With Myeloma. <i>American Journal of Clinical Pathology</i> , 2018, 150, 121-129.	0.7	28

#	ARTICLE	IF	CITATIONS
19	Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 326-335.	0.4	27
20	Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in <sc>MAMMOTH</sc>. <i>American Journal of Hematology</i> , 2021, 96, E5-E8.	4.1	20
21	A Phase I Study of Ixazomib in Combination with Panobinostat and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2015, 126, 4221-4221.	1.4	19
22	Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. <i>Leukemia</i> , 2022, 36, 877-880.	7.2	18
23	Identification of Long Non-coding RNAs Deregulated in Multiple Myeloma Cells Resistant to Proteasome Inhibitors. <i>Genes</i> , 2016, 7, 84.	2.4	15
24	Nivolumab before and after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 1054-1056.	2.4	15
25	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. <i>Cancer</i> , 2021, 127, 82-92.	4.1	15
26	Socioeconomic Factors and Survival of Multiple Myeloma Patients. <i>Cancers</i> , 2021, 13, 590.	3.7	14
27	Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle. <i>Frontiers in Oncology</i> , 2017, 7, 287.	2.8	12
28	Low dose anti-thymocyte globulin reduces chronic graft-versus-host disease incidence rates after matched unrelated donor transplantation. <i>Leukemia and Lymphoma</i> , 2018, 59, 1644-1651.	1.3	11
29	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2443-2449.	2.0	11
30	Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected. <i>Leukemia and Lymphoma</i> , 2019, 60, 2199-2206.	1.3	10
31	Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy. <i>Blood</i> , 2018, 132, 2015-2015.	1.4	10
32	Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies. <i>Blood</i> , 2019, 134, 3125-3125.	1.4	10
33	Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e213-e220.	0.4	9
34	Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma-specific venous thrombosis prediction models. <i>American Journal of Hematology</i> , 2020, 95, 918-926.	4.1	8
35	DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Seminars in Hematology</i> , 2021, 58, 45-55.	3.4	8
36	Racial and age-related disparities in early mortality affect the outcomes of multiple myeloma patients. <i>Leukemia</i> , 2021, 35, 250-254.	7.2	8

#	ARTICLE	IF	CITATIONS
37	Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1905-1912.	1.3	7
38	Natural History of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody-Based Treatment. <i>Blood</i> , 2018, 132, 3233-3233.	1.4	6
39	Continuous Temperature Monitoring for Earlier Fever Detection in Neutropenic Patients: Patient's Acceptance and Comparison with Standard of Care. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S108-S109.	2.0	5
40	Identifying Neutropenic Fever Earlier: An Application of a Skin Patch for Continuous Temperature Monitoring. <i>Blood</i> , 2018, 132, 4718-4718.	1.4	5
41	Serum electrolyte dynamics in multiple myeloma patients undergoing autologous haematopoietic stem cell transplantation. <i>Nephrology</i> , 2020, 25, 450-456.	1.6	4
42	Preclinical Studies and a Phase I Trial of the TGF- β 2 Receptor Inhibitor, Vactosertib (TEW-7197), in Combination with Pomalidomide in Patients with Multiple Myeloma Refractory to Bortezomib or Lenalidomide. <i>Blood</i> , 2018, 132, 1962-1962.	1.4	4
43	Vactosertib, a TGF- β 2 Receptor I Kinase/ALK5 Inhibitor, Diminishes Tumor Progression and Bone Disease in a Mouse Model of Multiple Myeloma and Overcomes Resistance to Proteasome Inhibitors. <i>Blood</i> , 2018, 132, 1918-1918.	1.4	4
44	Preclinical Studies and Phase I Trial of Vactosertib in Combination with Pomalidomide in Relapsed Multiple Myeloma: A Corticosteroid-Free Approach By Targeting TGF- β 2 Signaling Pathway. <i>Blood</i> , 2019, 134, 3232-3232.	1.4	4
45	Cardiovascular Toxicity after Therapy for Diffuse Large B Cell Lymphoma Occurs Early and Results in Decreased Overall Survival.. <i>Blood</i> , 2016, 128, 105-105.	1.4	4
46	High throughput chemical library screening identifies a novel p110- β inhibitor that potentiates the anti-myeloma effect of bortezomib. <i>Oncotarget</i> , 2016, 7, 38523-38538.	1.8	4
47	FDG PET imaging in multiple myeloma: implications for response assessments in clinical trials. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 8, 421-427.	1.0	4
48	Predicting Successful Phase Advancement and Regulatory Approval in Multiple Myeloma From Phase I Overall Response Rates. <i>JCO Clinical Cancer Informatics</i> , 2017, 1, 1-14.	2.1	3
49	Timing Embryo Preservation for a Patient with High-Risk Newly Diagnosed Acute Myeloid Leukemia. <i>Case Reports in Hematology</i> , 2018, 2018, 1-3.	0.4	3
50	Reducing Gastrointestinal Toxicity Associated with Autologous Transplantation for Multiple Myeloma without Compromising Its Anti-Myeloma Effect. <i>Blood</i> , 2017, 130, 680-680.	1.4	3
51	Real world vs. clinical trial outcomes of triple class refractory penta-exposed multiple myeloma (MM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e115-e116.	0.4	2
52	Efficacy and cost-benefit of filgrastim administered after early assessment bone marrow biopsy during induction therapy for acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1450-1457.	1.3	2
53	Pomalidomide + Low-Dose Dexamethasone Following Second-Line Lenalidomide-Based Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Study Investigating Efficacy and Safety. <i>Blood</i> , 2016, 128, 4497-4497.	1.4	2
54	Inotuzumab Ozogamicin Post-Transplant for Acute Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 1948-1948.	1.4	2

#	ARTICLE	IF	CITATIONS
55	Risk Model to Predict Supraventricular Arrhythmias in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S156-S157.	2.0	1
56	Dynamics of Serum Electrolyte Changes at the Peri-Engraftment Period in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S138-S140.	2.0	1
57	Risk of Progression Across Age and Race for Patients with Smoldering Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e325.	0.4	1
58	Comparison of Peripheral Blast Clearance and Day 14 Bone Marrow Biopsy in Predicting Remission Status and Survival After 7+3 Induction in Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 73-82.	0.4	1
59	Host and Disease Factors Impacting Presence of Accessory Band during Therapy with Daratumumab in Multiple Myeloma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S390.	2.0	1
60	Significant costs and low utilization of stored peripheral blood stem cells for salvage autologous transplant in multiple myeloma patients including those meeting mSMART criteria. <i>Bone Marrow Transplantation</i> , 2021, 56, 1458-1461.	2.4	1
61	Natural History of Patients with Multiple Myeloma Refractory to Elotuzumab and Outcomes of Subsequent Therapy with Anti-CD38 Monoclonal Antibodies. <i>Blood</i> , 2018, 132, 3303-3303.	1.4	1
62	Patterns of Care of Diffuse Large B Cell Lymphoma Patients 80 Years and Older: Worse Outcomes after Treatment without Increased Relapse. <i>Blood</i> , 2018, 132, 575-575.	1.4	1
63	Low Dose Antithymocyte Globulin (ATG) for Graft-Versus-Host Disease (GVHD) Prophylaxis. <i>Blood</i> , 2016, 128, 5788-5788.	1.4	1
64	Pharmacogenomics of Bortezomib in Multiple Myeloma Patients Reveals That the Ubiquitin Ligase SCF-Skp2 Promotes Drug Resistance. <i>Blood</i> , 2015, 126, 3021-3021.	1.4	1
65	Immunologic Status Evaluated By the Absolute Lymphocyte/Monocyte Ratio Provides a Powerful Prognostic Tool for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2016, 128, 1862-1862.	1.4	1
66	Comparison of Pegfilgrastim and Filgrastim to Prevent Neutropenic Fever during Consolidation with High Dose Cytarabine for Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1404-1404.	1.4	1
67	Stem Cell Transplant Minimizes Insurance Coverage-Driven Outcomes Disparities for Multiple Myeloma Patients. <i>Blood</i> , 2019, 134, 424-424.	1.4	1
68	Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 2899-2899.	1.4	1
69	Low Dose Daily Corticosteroid Tapering Regimen Allows Highly Effective and Practical Desensitization for Multiple Myeloma Patients with Skin Rash after Immunomodulatory Drugs. <i>Blood</i> , 2020, 136, 19-20.	1.4	1
70	Resistant or Sensitive: Time is of the Essence. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1907-1908.	2.0	0
71	Early Versus Late Initiation of Granulocyte Colony Stimulating Factor (G-CSF) Following Autologous Hematopoietic Stem Cell Transplantation in Adult Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S138-S139.	2.0	0
72	Venous Thromboembolic Events in Diffuse Large B Cell Lymphoma Patients: Risk Factors and Outcomes. <i>Blood</i> , 2016, 128, 3611-3611.	1.4	0

#	ARTICLE	IF	CITATIONS
73	A Phase I Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML). Blood, 2016, 128, 4065-4065.	1.4	0
74	Rethinking Risk-Benefit Assessment for Phase I Multiple Myeloma Trials. Blood, 2016, 128, 1146-1146.	1.4	0
75	Venous thromboembolism (VTE) in multiple myeloma (MM) patients undergoing autologous hematopoietic cell transplantation (HCT).. Journal of Clinical Oncology, 2017, 35, e19503-e19503.	1.6	0
76	Impact of Maintenance Therapy on Nature of First Relapse in Multiple Myeloma Patients Underwent Autologous Stem Cell Transplant. Blood, 2018, 132, 2130-2130.	1.4	0
77	Relative Abundance Analysis of the Oral and Gastrointestinal Microbiome during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study and Association with Transplant Outcomes. Blood, 2018, 132, 5754-5754.	1.4	0
78	Presence of Chip-Mutated Autologous Hematopoietic Cells in Mobilized Peripheral Blood Products Is Associated with Shorter Progression-Free Survival after Autologous Transplants for Multiple Myeloma. Blood, 2019, 134, 515-515.	1.4	0
79	A highly effective and practical desensitization regimen: Results in comparable clinical outcomes for multiple myeloma patients with skin rash after immunomodulatory drugs.. Journal of Clinical Oncology, 2020, 38, 12104-12104.	1.6	0
80	A phase II, single-arm study of denosumab in multiple myeloma patients with renal insufficiency.. Journal of Clinical Oncology, 2020, 38, 8520-8520.	1.6	0
81	Epigenetic Priming with Pre-Transplant Oral Panobinostat Followed By Post-Transplant Consolidation. Blood, 2021, 138, 2917-2917.	1.4	0
82	Mycobiome Supporting Diet to Reduce Gastrointestinal (GI) Toxicity Associated with Autologous Stem Cell Transplant (ASCT) for Patients with Multiple Myeloma (MM). Blood, 2021, 138, 3948-3948.	1.4	0
83	Health Care Burden of Monogammopathy of Renal Significance. Blood, 2020, 136, 34-36.	1.4	0
84	Development of a Machine Learning Algorithm for Rapid, Point-of-Care Prediction of Serum Monoclonal Proteins in Multiple Myeloma. Blood, 2020, 136, 13-15.	1.4	0
85	Patient Selection Bias Limits the Real World Efficacy of Randomized Clinical Trials in Multiple Myeloma. Blood, 2020, 136, 1-2.	1.4	0